Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Dr María Natalia Gandur Quiroga speaks to ecancer at ASCO GU 2026 regarding the latest advances in localised and biochemically recurrent prostate cancer.
She says this is a field rapidly evolving towards smarter, more personalised treatment strategies.
This year’s data highlights a critical shift in oncology: moving beyond simply intensifying treatment to carefully selecting who truly benefits.
Dr Gandur highlights that in 2026, prostate cancer care is no longer just about doing more, it’s about doing what’s right for the right patient.
| Fifteen-year survival analysis from the ASCENDE-RT randomized trial of external beam boost versus brachytherapy boost in localized prostate cancer. | |
| Hormone therapy use and duration with post-operative radiotherapy for recurrent prostate cancer: An individual patient data meta-analysis | |
| A randomized phase 2 study of enhanced AR blockade with enzalutamide in high-risk patients with biochemical relapse undergoing salvage radiation: Final results from RTOG 3506 (STEEL) | |
| Efficacy and safety of darolutamide monotherapy in patients with castration-sensitive prostate cancer (CSPC) after biochemical recurrence (BCR): 52-week results from ARAMON | |
| Are long-term remissions possible with hormonal therapy only? Post hoc analysis of EMBARK | |
| COACTION: A Randomized Trial of Neoadjuvant Leuprorelin, Darolutamide, or Both Prior to Radical Prostatectomy for Intermediate- or High-Risk Prostate Cancer |
